First-Line Lenvatinib in Child-Pugh B Patients With HCC Unsuitable for Curative Treatment: A Phase 2 FINELAND Trial
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 50
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
This study aims to evaluate the efficacy and safety of lenvatinib as first-line therapy in patients with Child-Pugh class B HCC who are unsuitable for curative treatment.
详细描述
<Treatment Phase> All participants will receive lenvatinib treatment after signing informed consent. Lenvatinib will be administered orally once daily at a dose of 8 mg, at the same time each day, with or without food.
Treatment must begin within 3 days after screening and will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
<Follow-up Phase> After the treatment phase, participants will be followed every 12 weeks (±7 days) after the last dose for survival status and use of subsequent anticancer therapies. Survival follow-up will be conducted for at least 12 months after enrollment of the last participant.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Age ≥ 19 years at the time of signing informed consent
- •Histological or clinical diagnosis of HCC according to the Korean Liver Cancer Association-National Cancer Center guidelines
- •HCC not amenable to curative treatment (e.g., surgical resection, local therapy, liver transplantation)
- •At least one measurable target lesion according to RECIST v1.1
- •- Participants who previously received local treatment (e.g., radiofrequency ablation, microwave ablation, transarterial chemoembolization, transarterial radioembolization, transarterial embolization, or radiotherapy) are eligible if (a) target lesions have not been treated by prior local therapy, or (b) lesions within the field of local therapy have subsequently progressed according to RECIST v1.
- •Child-Pugh class B7-B8
- •ECOG performance status (PS) 0-2
- •Adequate hematologic and end-organ function defined by the following laboratory tests obtained within 14 days prior to screening:
- •Hemoglobin ≥ 8.0g/dL
- •Absolute neutrophil count (ANC) ≥ 1,000/mm3
- •Platelet count ≥ 50,000/μL
- •Total bilirubin < 3.5 mg/dL
- •Serum albumin ≥ 2.5 g/dL
- •ALT and AST ≤ 7 x upper limit of normal (ULN)
- •Prothrombin time (INR ≤ 1.8 × ULN)
- •Serum creatinine ≤ 2.0 × ULN or calculated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault equation)
- •Documented virological status for hepatitis B virus (HBV) and hepatitis C virus (HCV) by screening tests.
- •- Participants with HBV or HCV infection must receive antiviral therapy in accordance with institutional guidelines.
- •Women of childbearing potential must agree to remain abstinent or use effective contraception (failure rate < 1% per year) from signing informed consent through at least 6 months after the last study drug administration.
- •Men must agree to remain abstinent or use effective contraception (failure rate < 1% per year) during the same period and refrain from sperm donation.
排除标准
- •Fibrolamellar carcinoma or sarcomatoid carcinoma
- •Prior systemic therapy for HCC
- •Local therapy for HCC (including radiofrequency ablation, microwave ablation, cryoablation, transarterial chemoembolization, radioembolization, or radiotherapy) within 28 days prior to initiation of study treatment, or unresolved complications from such procedures
- •- Palliative radiotherapy to bone lesions is permitted with a 7-day washout
- •History of allogeneic stem cell or solid organ transplantation
- •Active brain metastases or leptomeningeal disease
- •History of another malignancy within 2 years prior to screening, except for cancers with negligible risk of metastasis or death (e.g., >90% 5-year survival)
- •Serious uncontrolled medical comorbidities within 3 months prior to study treatment, including severe cardiovascular disease (NYHA class ≥ II heart disease, myocardial infarction, or cerebrovascular accident), unstable arrhythmia, or unstable angina, or any condition judged by the investigator to increase participant risk
- •Pregnant or breastfeeding women, or men and women of reproductive potential unwilling to use effective contraception from screening through 6 months after the last study drug administration
- •Any condition judged by the investigator to interfere with compliance with study procedures, restrictions, or requirements
研究组 & 干预措施
Lenvatinib
Lenvatinib will be administered orally once daily at a dose of 8 mg, at the same time each day, with or without food.
Treatment must begin within 3 days after screening and will continue until disease progression, unacceptable toxicity, withdrawal of consent, or study termination, whichever occurs first.
干预措施: Lenvatinib (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred
Progression-free survival (PFS) is defined as the time from the date of treatment initiation to the date of first documented progressive disease (PD) according to RECIST v1.1, as assessed by the investigator, or death from any cause.
次要结局
- Overall survival (OS)(Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred)
- Time to progression (TTP)(Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred.)
- Objective response rate (ORR)(Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred.)
- Disease control rate (DCR)(Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred.)
- The incidence of AEs(Twelve months after the last subject is enrolled or the time at which the 41 events required to verify the assumptions used in the sample size calculation have occurred.)
研究者
Bo Hyun Kim
Principal Investigator
National Cancer Center, Korea